223 related articles for article (PubMed ID: 10551494)
21. p120-v-Abl expression overcomes TGF-beta1 negative regulation of c-myc transcription but not cell growth.
Birchenall-Roberts MC; Kim SJ; Bertolette DC; Turley JM; Fu T; Bang OS; Kasper JJ; Yoo YD; Ruscetti FW
Oncogene; 1996 Oct; 13(7):1499-509. PubMed ID: 8875988
[TBL] [Abstract][Full Text] [Related]
22. Association of Pur alpha and E2F-1 suppresses transcriptional activity of E2F-1.
Darbinian N; Gallia GL; Kundu M; Shcherbik N; Tretiakova A; Giordano A; Khalili K
Oncogene; 1999 Nov; 18(46):6398-402. PubMed ID: 10597240
[TBL] [Abstract][Full Text] [Related]
23. Gene therapy for human bypass grafts.
Mangi AA; Dzau VJ
Ann Med; 2001 Apr; 33(3):153-5. PubMed ID: 11370767
[TBL] [Abstract][Full Text] [Related]
24. The gene expression index c-myc x E2F-1/p21 is highly predictive of malignant phenotype in human bronchial epithelial cells.
DeMuth JP; Jackson CM; Weaver DA; Crawford EL; Durzinsky DS; Durham SJ; Zaher A; Phillips ER; Khuder SA; Willey JC
Am J Respir Cell Mol Biol; 1998 Jul; 19(1):18-24. PubMed ID: 9651176
[TBL] [Abstract][Full Text] [Related]
25. Intraoperative transfection of vein grafts with the NFkappaB decoy in a canine aortocoronary bypass model: a strategy to attenuate intimal hyperplasia.
Shintani T; Sawa Y; Takahashi T; Matsumiya G; Matsuura N; Miyamoto Y; Matsuda H
Ann Thorac Surg; 2002 Oct; 74(4):1132-7; discussion 1137-8. PubMed ID: 12400757
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of carotis venous bypass graft disease by intraoperative nucleic acid-based therapy in rabbits.
Kusch B; Waldhans S; Sattler A; Wagner A; Hecker M; Moosdorf R; Vogt S
Thorac Cardiovasc Surg; 2006 Sep; 54(6):388-92. PubMed ID: 16967374
[TBL] [Abstract][Full Text] [Related]
27. Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha.
Santoni-Rugiu E; Jensen MR; Thorgeirsson SS
Cancer Res; 1998 Jan; 58(1):123-34. PubMed ID: 9426068
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of anastomotic intimal hyperplasia using a chimeric decoy strategy against NFkappaB and E2F in a rabbit model.
Miyake T; Aoki M; Morishita R
Cardiovasc Res; 2008 Sep; 79(4):706-14. PubMed ID: 18515844
[TBL] [Abstract][Full Text] [Related]
29. Vitamin E succinate inhibits proliferation of BT-20 human breast cancer cells: increased binding of cyclin A negatively regulates E2F transactivation activity.
Turley JM; Ruscetti FW; Kim SJ; Fu T; Gou FV; Birchenall-Roberts MC
Cancer Res; 1997 Jul; 57(13):2668-75. PubMed ID: 9205075
[TBL] [Abstract][Full Text] [Related]
30. Small interfering RNA targeting nuclear factor kappa B to prevent vein graft stenosis in rat models.
Meng XB; Bi XL; Zhao HL; Feng JB; Zhang JP; Song GM; Sun WY; Bi YW
Transplant Proc; 2013; 45(6):2553-8. PubMed ID: 23953580
[TBL] [Abstract][Full Text] [Related]
31. Long-term reduction of medial and intimal thickening in porcine saphenous vein grafts with a polyglactin biodegradable external sheath.
Vijayan V; Shukla N; Johnson JL; Gadsdon P; Angelini GD; Smith FC; Baird R; Jeremy JY
J Vasc Surg; 2004 Nov; 40(5):1011-9. PubMed ID: 15557918
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic applications of transcription factor decoy oligonucleotides.
Mann MJ; Dzau VJ
J Clin Invest; 2000 Nov; 106(9):1071-5. PubMed ID: 11067859
[No Abstract] [Full Text] [Related]
33. The E2F-family proteins induce distinct cell cycle regulatory factors in p16-arrested, U343 astrocytoma cells.
Dirks PB; Rutka JT; Hubbard SL; Mondal S; Hamel PA
Oncogene; 1998 Aug; 17(7):867-76. PubMed ID: 9780003
[TBL] [Abstract][Full Text] [Related]
34. Transcription factor decoys for the prevention of vein bypass graft failure.
Mann MJ; Conte MS
Am J Cardiovasc Drugs; 2003; 3(2):79-85. PubMed ID: 14727934
[TBL] [Abstract][Full Text] [Related]
35. A direct role of transcription factor E2F in c-myc gene expression during granulocytic and macrophage-like differentiation of HL60 cells.
Ishida S; Shudo K; Takada S; Koike K
Cell Growth Differ; 1995 Mar; 6(3):229-37. PubMed ID: 7794791
[TBL] [Abstract][Full Text] [Related]
36. Regulation of E2F-1 gene expression by p130 (Rb2) and D-type cyclin kinase activity.
Johnson DG
Oncogene; 1995 Nov; 11(9):1685-92. PubMed ID: 7478595
[TBL] [Abstract][Full Text] [Related]
37. Cyclin E and c-Myc promote cell proliferation in the presence of p16INK4a and of hypophosphorylated retinoblastoma family proteins.
Alevizopoulos K; Vlach J; Hennecke S; Amati B
EMBO J; 1997 Sep; 16(17):5322-33. PubMed ID: 9311992
[TBL] [Abstract][Full Text] [Related]
38. Cell cycle gene expression and E2F transcription factor complexes in human melanoma cells induced to terminally differentiate.
Jiang H; Lin J; Young SM; Goldstein NI; Waxman S; Davila V; Chellappan SP; Fisher PB
Oncogene; 1995 Sep; 11(6):1179-89. PubMed ID: 7566979
[TBL] [Abstract][Full Text] [Related]
39. New therapeutic possibilities for vein graft disease in the post-edifoligide era.
Cai X; Freedman NJ
Future Cardiol; 2006 Jul; 2(4):493-501. PubMed ID: 19804184
[TBL] [Abstract][Full Text] [Related]
40. E2F-dependent regulation of human MYC: trans-activation by cyclins D1 and A overrides tumour suppressor protein functions.
Oswald F; Lovec H; Möröy T; Lipp M
Oncogene; 1994 Jul; 9(7):2029-36. PubMed ID: 8208548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
